ArticleJournal of orthopaedics2025
BMI-stratified risk of thromboembolic events following lumbar spine surgery with aspirin prophylaxis.
Article in Journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study design: Level of Evidence: Therapeutic Level III. Background and objective: Aspirin is commonly used for VTE prophylaxis in orthopedic procedures due to its safety and cost-effectiveness. However, its association with thromboembolic outcomes in obese and morbidly obese patients undergoing LSS remains unclear, particularly in the absence of BMI-specific prophylaxis guidelines. This study evaluates whether venous thromboembolism (VTE) event rates differ by body mass index (BMI) category in patients undergoing lumbar spine surgery (LSS) treated with aspirin monotherapy. Methods: This retrospective cohort study leveraged the TriNetX database to identify adults undergoing LSS who received aspirin monotherapy. Patients were stratified by BMI into non-obese (<30 kg/m Results: Obese patients had higher observed rates of 90-day DVT (RR: 1.23, 95 % CI: 1.02-1.48) and PE (RR: 1.45, 95 % CI: 1.14-1.84) compared to non-obese patients. At 180 days, PE risk remained elevated (RR: 1.27, 95 % CI: 1.03-1.57), while DVT risk was no longer statistically significant. Morbidly obese patients had a higher 180-day PE risk than the obese group (RR: 1.54, 95 % CI: 1.03-2.29). No significant differences were observed in hematoma or myocardial infarction across groups. Conclusion: Among patients undergoing LSS with aspirin monotherapy, PE risk remained elevated in obese and especially morbidly obese patients at 180 days, despite matched baseline characteristics. While differences were statistically significant, absolute risk increases were modest. These findings support the need for prospective studies to evaluate whether weight-adjusted dosing, alternative agents, or adjunctive mechanical prophylaxis may offer improved protection in high-BMI populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.